GlassScriptPhysician profile
Benjamin C Hubbard
NPI 1154588978
$2,659.82
in general payments reported to CMS, 2019-2025
19 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.23 · 2022: $48.10 · 2023: $213 · 2024: $1,887 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431 · Travel and Lodging: $1,094 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.58 |
| Travel and Lodging | $1,093.87 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,722.84 | 2023-2025 | Neurostar Tms Therapy System |
| Abbvie INC. | $177.93 | 2022-2025 | |
| Novo Nordisk INC | $106.79 | 2025 | Ozempic, Wegovy, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $105.18 | 2022-2024 | Austedo Xr, Uzedy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.97 | 2023-2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.40 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $72.50 | 2025 | Zepbound |
| Amgen INC. | $50.77 | 2019 | |
| Corcept Therapeutics | $50.10 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $25.89 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $24.47 | 2024 | Trintellix |
| Pfizer INC. | $23.04 | 2023 | |
| Janssen Pharmaceuticals, INC | $20.20 | 2023 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $19.77 | 2023 | Abilify Maintena, Rexulti |
| Ironshore Pharmaceuticals INC. | $18.91 | 2023 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.02 | 2025 | Auvelity |
| Alkermes, INC. | $16.08 | 2024 | Lybalvi |
| Boston Scientific Corporation | $15.50 | 2025 | Ams 700 |
| Circassia INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.